What the studies show
Well tolerated over seven days of IV dosing in the ileus trial. No long-term human safety data at the doses and durations used on the grey market.
A few small or poorly-controlled human studies. Enough to be interesting; not enough to count on. Most of what gets called “clinically proven” online lives here.
- 1Beck DE, Sweeney WB, McCarter MD, et al. Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.Int J Colorectal Dis, 2014;29:1527–1534117 patients; primary endpoint not met (p=0.15).
In context
Ipamorelin is a synthetic five-amino-acid peptide that stimulates growth-hormone release with little effect on cortisol or prolactin. Small early studies confirmed the hormone release; the only randomised trial — 117 bowel-surgery patients, testing it for post-operative gut recovery — found no benefit, and development stopped. It is not an approved medicine anywhere, and the popular claims about muscle, fat loss and sleep have never been tested in a trial.
Ipamorelin is not approved. Legal status differs by country — see the regulation section or the jurisdiction pages.
Questions
Is Ipamorelin proven to cause safety in humans?
What studies are behind the grade?
Is Ipamorelin approved for this?
Other outcomes for Ipamorelin
- CGrowth hormone releaseSmall early-phase studies
- CPost-operative ileus (gut recovery)1 RCT (n=117)
- DBody compositionNone controlled
- DSleep or recoveryNone
Reviewed 2 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →